
Dataset EV5. Drug sensitivity data for top INKA-scoring kinases in four cancer cell line use cases. 

Cell line-specific IC50 values, and Z-scores indicating relative sensitivity to a given drug compared to all other cell lines, for top INKA-scoring kinases in:

a) K562 driven by BCR-ABL. The data show high sensitivity of the cell line only to inhibitors of ABL.
b) SK-Mel-28 driven by BRAF. Drug inhibition data are also listed for BRAF and ERK-activating MEKs in addition to top INKA-scoring kinases. Among the latter, ERK1 and ERK2 exhibit limited sensitivity to inhibitors. Direct targeting of BRAF, or (upstream of ERK1/2) MEK1/2, is much more successful, in line with BRAF driver function. 
c) HCC827 driven by EGFR. HCC827, the erlotinib-sensitive parental line of the erlotinib-resistant HCC827-ER3 sub-line, exhibits high sensitivity to EGFR inhibitors, but not MET inhibitors.
d) H2228 associated with EML4-ALK. The data show moderate sensitivity of H2228 to ALK inhibitors, but little efficacy of inhibitors targeting top INKA-scoring kinases. 

Data were derived from the Genomics of Drug Sensitivity in Cancer website (GDSC, http://www.cancerrxgene.org). Download of 31 October 2017.

